The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 07, 2026
Filed:
Feb. 26, 2021
Daegu-gyeongbuk Medical Innovation Foundation, Daegu, KR;
Immunoforge Co., Ltd., Seoul, KR;
Doohyun Lee, Daegu, KR;
Seungyeon Lee, Daegu, KR;
Ye Ri Han, Daegu, KR;
Chun Young Im, Daegu, KR;
So Young Kim, Daegu, KR;
Nam Hui Kim, Daegu, KR;
Hwan Geun Choi, Seoul, KR;
Eunhwa Ko, Incheon, KR;
Heegyum Moon, Daegu, KR;
Sun Joo Lee, Daegu, KR;
Sang Bum Kim, Daegu, KR;
Hyo-Ji Kim, Daegu, KR;
Sion Lee, Daegu, KR;
Sung-Min Ahn, Seoul, KR;
Kiho Chang, Seoul, KR;
Eunkyu Lee, Seoul, KR;
Hyun Jin Kwon, Seoul, KR;
Myeong-Sook Jeong, Seoul, KR;
Ji Young Kim, Seoul, KR;
Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, KR;
Immunoforge Co., Ltd., Seoul, KR;
Abstract
The present invention relates to a 3-((8-((1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)-N-phenylbenzamide derivative, a method for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient for preventing or treating cancer. The derivative can significantly inhibit the proliferation of cancer cells by inhibiting kinases, particularly Bcr-Abl kinase or Bcr-Abl (T315I) kinase. Therefore, the derivative can be effectively used as a pharmaceutical composition for the prevention or treatment of cancer.